Kesmalea Therapeutics
Myrianni Constantinou is a scientist with a background in cancer genomics, holding a Ph.D. from Queen Mary University of London, where studies were completed between 2019 and 2023. Prior to that, Myrianni obtained a Master of Research (MRes) in Cellular and Molecular Neuro-oncology from the University of Portsmouth in 2017. Myrianni has extensive research experience, including roles as a postdoctoral researcher at the Blizard Institute and a visiting researcher at the University of Portsmouth. Additional positions include volunteer research assistant and student ambassador, demonstrating a strong commitment to academic and community engagement. Currently, Myrianni works as a scientist at Kesmalea Therapeutics.
This person is not in any teams
Kesmalea Therapeutics
1 followers
Kesmalea is creating a new generation of protein homeostasis modulators, with a unique chemistry platform technology and therapeutic paradigm. Our novel approach allows us to overcome the challenges of existing protein degradation and stabilisation technologies, opening the door to previously unavailable oral therapeutics in areas of high unmet medical need. Protein homeostasis is the system of maintaining the equilibrium of proteins in the human body. This intricate system is in a constant state of change, with the body continuously synthesising and regulating proteins, whilst removing those which are no longer required (or have mutated) through controlled degradation. Small perturbations of the human body’s natural control mechanism that result in an excess or absence of certain proteins can drive the progression of disease. At Kesmalea, we’re aiming to counter this dysregulation with novel treatments which restore balance through effective protein degradation or stabilisation.